Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopap...
Main Authors: | Xiaoyan SI, Chunxia HE, Li ZHANG, Xiaowei LIU, Yue LI, Hanping WANG, Xiaoxiao GUO, Jiaxin ZHOU, Lian DUAN |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-10-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.06 |
Similar Items
-
Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01) -
Clinical Diagnosis and Treatment Recommendations for Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor
by: Xiaoxiao GUO, et al.
Published: (2019-10-01) -
Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01) -
Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01) -
Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy
by: Xiaowei LIU, et al.
Published: (2019-10-01)